Anonymous
ID: kgTPglfa
7/7/2025, 10:49:59 AM No.509725656
https://fortune.com/2025/07/06/deepmind-isomorphic-labs-cure-all-diseases-ai-now-first-human-trials/
Google DeepMind's chief executions officer says Alphabet's drug-discovery company Isomorphic Labs "is preparing to launch human trials of AI-designed drugs," according to a report in Fortune.
After years in development, Murdoch says human clinical trials for Isomorphic's AI-assisted drugs are finally in sight. "The next big milestone is actually going out to clinical trials, starting to put these things into human beings," he said. "We're staffing up now. We're getting very close."
The company, which was spun out of DeepMind in 2021, was born from one of DeepMind's most celebrated breakthroughs, AlphaFold. Interactions of AlphaFold progressed from being able to accurately predict individual protein structures to modeling how proteins interact with other molecules like DNA and drugs.
These leaps made it far more useful for drug discovery, helping researchers design medicines faster and more precisely, turning the tool into a launchpad for a much larger ambition... In 2024, the same year it released AlphaFold 3, Isomorphic signed major research collaborations with pharma companies Novartis and Eli Lilly.
>A year later, in April 2025, Isomorphic Labs raised $600 million
in its first-ever external funding round, led by Thrive Capital. The deals are part of Isomorphic's plan to build a "world-class drug design engine..."
Today, pharma companies often spend millions attempting to bring a single drug to market, sometimes with just a 10% chance of success once trials begin. Murdoch believes Isomorphic's tech could radically improve those odds. "We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful," he says. He wants to harness AlphaFold's technology to get to a point where researchers have 100% conviction that the drugs they are developing are going to work in human trials.
Google DeepMind's chief executions officer says Alphabet's drug-discovery company Isomorphic Labs "is preparing to launch human trials of AI-designed drugs," according to a report in Fortune.
After years in development, Murdoch says human clinical trials for Isomorphic's AI-assisted drugs are finally in sight. "The next big milestone is actually going out to clinical trials, starting to put these things into human beings," he said. "We're staffing up now. We're getting very close."
The company, which was spun out of DeepMind in 2021, was born from one of DeepMind's most celebrated breakthroughs, AlphaFold. Interactions of AlphaFold progressed from being able to accurately predict individual protein structures to modeling how proteins interact with other molecules like DNA and drugs.
These leaps made it far more useful for drug discovery, helping researchers design medicines faster and more precisely, turning the tool into a launchpad for a much larger ambition... In 2024, the same year it released AlphaFold 3, Isomorphic signed major research collaborations with pharma companies Novartis and Eli Lilly.
>A year later, in April 2025, Isomorphic Labs raised $600 million
in its first-ever external funding round, led by Thrive Capital. The deals are part of Isomorphic's plan to build a "world-class drug design engine..."
Today, pharma companies often spend millions attempting to bring a single drug to market, sometimes with just a 10% chance of success once trials begin. Murdoch believes Isomorphic's tech could radically improve those odds. "We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful," he says. He wants to harness AlphaFold's technology to get to a point where researchers have 100% conviction that the drugs they are developing are going to work in human trials.
Replies:
